|
|
|
|
|
市場調査レポート
前立腺癌の薬剤開発動向
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
|
Abstract
This report aims to analyze the current and future potential of prostate
cancer pipeline by examining key fundamentals across the entire pipeline of
drug candidates. BioSeeker has identified three fundamental dimensions to
outline the competitive landscape within the pharmaceutical industry; compound
type, therapy area and target type.
This report is written for you to identify your competition and understand
which targeting strategies are at work within prostate cancer drug
development. It allows you to pin-point which competitors drugs' clinical
out-come may have bearing on your own drug development and who are developing
sequels to blockbuster drugs. This report also helps you to locate white-spots
in the competitive landscape, giving you little or no competition. Conversely
it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. BioSeeker has surveyed the prostate cancer
field and identified 135 drug targets belonging to 193 drugs. This report,
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is
an open landscape of resources to build, fuel, and drive your scientific
competitive vehicle for the advancement of prostate cancer drugs.
In the report, BioSeeker reports on 116 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 193 prostate cancer drugs. The highest degree of distinctiveness among the
cancer drugs is achieved by sorting each of them according to drug target mix,
compound type and R&D approach. At the same time we are also identifying peer
groups of drugs, that is, drugs we consider suitable for head-to-head
comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of prostate drugs. No less than 300+ target-target interactions were
recognized among and between 110 of the 135 included prostate cancer drug
targets.
Why You Should Own Your Own Copy of this Report:
- 300+ pages, with more than 50 different tables and figures. Includes more
than 1,000 active links to drug target related resources on the Internet
- A 193 prostate cancer drugs analysis, under development by 135
investigators
- 135 unique, in-depth, drug target validating profiles, highlighting twelve
themes about the drug target, i.e. protein-protein interaction with other
prostate cancer drug targets, pursued cancer indications, drugs under
development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of prostate cancer drugs into
R&D approaches
- Unique drug-protein target interactome- and protein-protein interactome of
drug targets analysis
- Pathway profiling of prostate cancer drug targets
- Compound strategies based on sub-cellular localization of drug targets
- Expression levels of identified drug targets in prostate cancer tissue
- Structure based drug design in prostate cancer
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
Table of Contents
1. Executive Summary
2. About Cancer Highlights
3. Methodologies
4. Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5. How to Use this Report
6. Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Targets
7. The Cancer Genome Project and Prostate Cancer Targets
- 7.1 Prostate Cancer Targets Present in the Cancer Gene Census and in the
Catalogue Somatic Mutations in Cancer
8. Expression Levels of Identified Drug Targets in Prostate Cancer Tissue
9. Pathway Analysis of Prostate Cancer Drugs
10. Target-Target Interactions among Identified Prostate Cancer Targets
11. Structure-based Drug Design in Prostate Cancer is Stimulated by Available
- Data on Biological Targets
12. Drug Target Profiles of Prostate Cancer Drugs
- 12.1.1 Acid Phosphatase Activity Targets
- 12.1.2 Carboxy-Lyase Activity Targets
- 12.1.3 Carboxypeptidase Activity Targets
- 12.1.4 Catalytic Activity Targets
- 12.1.5 Cell Adhesion Molecule Activity Targets
- 12.1.6 Chaperone Activity Targets
- 12.1.7 Chemokine Activity Targets
- 12.1.8 Complement Activity Targets
- 12.1.9 Cysteine-Type Peptidase Activity Targets
- 12.1.10 Cytokine Activity Targets
- 12.1.11 DNA Repair Protein Targets
- 12.1.12 DNA Topoisomerase Activity Targets
- 12.1.13 DNA-Directed DNA Polymerase Activity Targets
- 12.1.14 G-Protein Coupled Receptor Activity Targets
- 12.1.15 Growth Factor Activity Targets
- 12.1.16 Hydrolase Activity Targets
- 12.1.17 Kinase Activity Targets
- 12.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
- 12.1.19 Ligase Activity Targets
- 12.1.20 Lipid Kinase Activity Targets
- 12.1.21 Lipid Phosphatase Activity Targets
- 12.1.22 Metallopeptidase Activity Targets
- 12.1.23 Molecular Function Unknown Targets
- 12.1.24 Motor Activity Targets
- 12.1.25 Oxidoreductase Activity Targets
- 12.1.26 Peptide Hormone Targets
- 12.1.27 Protein Binding Targets
- 12.1.28 Protein Serine/Threonine Kinase Activity Targets
- 12.1.29 Protein-Tyrosine Kinase Activity Targets
- 12.1.30 Receptor Activity Targets
- 12.1.31 Receptor Binding Targets
- 12.1.32 Receptor Signaling Complex Scaffold Activity Targets
- 12.1.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
- 12.1.34 RNA Binding Targets
- 12.1.35 RNA-Directed DNA Polymerase Activity Targets
- 12.1.36 Serine-Type Peptidase Activity Targets
- 12.1.37 Structural Constituent of Cytoskeleton Targets
- 12.1.38 Structural Molecule Activity Targets
- 12.1.39 Superoxide Dismutase Activity Targets
- 12.1.40 T Cell Receptor Activity Targets
- 12.1.41 Transcription Factor Activity Targets
- 12.1.42 Transcription Regulator Activity Targets
- 12.1.43 Translation Regulator Activity Targets
- 12.1.44 Transmembrane Receptor Activity Targets
- 12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 12.1.46 Transporter Activity Targets
13. The Drug-Target Interactome
14. The Progression and Maturity of Prostate Cancer Targets
- 14.1 Target Profiles of Prostate Cancer Drugs in Pre-Registration or on
the Market
- 14.2 New and Unique Prostate Cancer Targets in Phase III Clinical
Development
- 14.3 New and Unique Prostate Cancer Targets in Phase II Clinical
Development
- 14.4 New and Unique Prostate Cancer Targets in Phase I Clinical Development
- 14.5 New and Unique Prostate Cancer Targets in Preclinical Development
- 14.6 Development Profiles of All Prostate Cancer Target Combinations
15. Targets by R&D Approach in Prostate Cancer
- 15.1 Small Molecules
- 15.1.1 Background
- 15.1.2 Targets in Prostate Cancer
- 15.2 Peptide/Protein Drugs
- 15.2.1 Background
- 15.2.2 Targets in Prostate Cancer
- 15.3 Monoclonal Antibodies and Antibody-Like Structures
- 15.3.1 Background
- 15.3.2 Targets in Prostate Cancer
- 15.4 Nucleic Acid Therapies
- 15.4.1 Background
- 15.4.2 Targets in Prostate Cancer
- 15.5 Cell and Gene Therapy
- 15.5.1 Background
- 15.5.2 Targets in Prostate Cancer
- 15.6 Drug Delivery and Nanotechnology
- 15.6.1 Background
- 15.6.2 Targets in Prostate Cancer
16. Prostate Cancer Targets by Companies
- 16.1 Australia
- 16.2 Canada
- 16.3 Denmark
- 16.4 Finland
- 16.5 France
- 16.6 Germany
- 16.7 India
- 16.8 Ireland
- 16.9 Israel
- 16.10 Italy
- 16.11 Japan
- 16.12 Netherlands
- 16.13 Norway
- 16.14 Spain
- 16.15 Sweden
- 16.16 Switzerland
- 16.17 United Kingdom
- 16.18 USA
- 16.19 Non-Industrial Bodies
17. Drug Index
18. Company Index
List of Figures
- Figure 1: Distribution of Compound Types among Prostate Cancer Drugs
- Figure 2: Primary Sub-cellular Localization of Drug Targets
- Figure 3: Visualization of Protein-Protein Interactions Among Antibody
Drug Targets
- Figure 4: The Drug-Protein Interactome of Prostate Cancer Drugs - Main
Clusters
- Figure 5: The Drug-Protein Interactome of Prostate Cancer Drugs - Smaller
Clusters
- Figure 6: Head-to-Head Targeting Interactome of Prostate Cancer Drugs
- 4.2 List of Tables
- Table 1: Compound Strategies based on Sub-Cellular Localization of
Prostate Cancer Drug Targets
- Table 2: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of
Somatic Mutations in Cancer the Cancer Gene Census
- Table 3: Expression Levels of Identified Drug Targets in Prostate Cancer
Tissue
- Table 4: Pathway Summary
- Table 5: Drug Targets without any Identified Assigned Pathways
- Table 6: Pathway Profile According to BioCarta of Prostate Cancer Drug
Targets
- Table 7: Pathway Profile According to BioCarta of Prostate Cancer Drug
Targets
- Table 8: Pathway Profile According to BioCarta of Prostate Cancer Drug
Targets
- Table 9: Target-Target Interactions among Prostate Cancer Drug Targets
- Table 10: Identity of Prostate Cancer Drug Targets with Available
Biological Structures
- Table 11: Overview of Drug Target Profile Themes
- Table 12: Drug-Protein Interactome Clusters
- Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes,
Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
- Table 14: Top 5 Competitive Prostate Cancer Targets
- Table 15: Target Profiles of Prostate Cancer Drugs in Pre-Registration or
on the Market
- Table 16: New and Unique Prostate Cancer Targets in Phase III Clinical
Development
- Table 17: New and Unique Prostate Cancer Targets in Phase II Clinical
Development
- Table 18 New and Unique Prostate Cancer Targets in Phase I Clinical
Development
- Table 19: New and Unique Prostate Cancer Targets in Preclinical Development
- Table 20: The Progression, Maturity and Competitive Comparison of Prostate
Cancer Drug Targets in Development
- Table 21: Number of Prostate Cancer Drug Target Mixes Reported by Line of
Therapy
- Table 22: Number of Head-to-head Competing Small Molecule Drugs for the
Treatment of Prostate Cancer Drug Target
- Table 23: Drug Targets of Small Molecule Drugs in Prostate Cancer
- Table 24: Mechanistic Relationship between Small Molecule Drugs in
Prostate Cancer
- Table 25: Drug Targets of Peptide Based Drugs in Prostate Cancer
- Table 26: Drug Targets of Protein Based Drugs in Prostate Cancer
- Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in
Prostate Cancer
- Table 28: Drug Targets of Nucleic Acid Therapies in Prostate Cancer
- Table 29: Potential Forms of Cell Therapy
- Table 30: Vectors in Gene Therapy
- Table 31: Drug Targets of Cell Therapies in Prostate Cancer
- Table 32: Drug Targets of Gene Therapies in Prostate Cancer
- Table 33: Drug Targets with New Drug Delivery Strategies in Prostate Cancer
- Table 34: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Australia
- Table 35: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Canada
- Table 36: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Denmark
- Table 37: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Finland
- Table 38: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in France
- Table 39: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Germany
- Table 40: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in India
- Table 41: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Ireland
- Table 42: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Israel
- Table 43: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Italy
- Table 44: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Japan
- Table 45: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Netherlands
- Table 46: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Norway
- Table 47: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Spain
- Table 48: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Sweden
- Table 49: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in Switzerland
- Table 50: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in United Kingdom
- Table 51: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Companies in USA
- Table 52: Prostate Cancer Drugs with Drug Target Mix and Developmental
Projects by Non-Industrial Bodies
|
 |
